Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering - PubMed
5 hours ago
- #PCSK9 inhibitor
- #lipid-lowering therapy
- #monoclonal antibody
- Recaticimab is the first Fc-engineered PCSK9 monoclonal antibody designed for more long-lasting lipid-lowering effects.
- It incorporates the YTE mutation (M252Y/S254T/T256E) to prolong half-life via enhanced FcRn binding, allowing dosing intervals up to 12 weeks.
- Phase III trials show potent and sustained LDL-C reduction as monotherapy or with statins, with a favorable safety profile.
- Recaticimab may address limitations of existing PCSK9 inhibitors, such as frequent injections and suboptimal real-world adherence.
- Further validation is needed in broader populations, as current evidence mainly comes from studies in Chinese populations.
- Future studies should evaluate its impact on real-world adherence, cardiovascular outcomes, and cost-effectiveness.